| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.kimiabiosciences.com | |
| Market Cap | 244.13 Cr. | |
| Enterprise Value(EV) | 293.08 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -2.80 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.97 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | -0.35 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | -148.75 | Calculated using Price: 51.60 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 4.73 Cr. | 47,312,741 Shares |
| FaceValue | 1 | |
| About Kimia Biosciences Ltd. | ||
| The company is a pharmaceutical company and the state of the art manufacturing facility is manufacturing latest Bulk Drugs and intermediates (R&D based) for India and Overseas markets. | ||
| 1 Day |
|
-1.41% |
| 1 Week |
|
-3.20% |
| 1 Month |
|
-4.93% |
| 3 Month |
|
+40.09% |
| 6 Month |
|
+46.81% |
| 1 Year |
|
+46.06% |
| 2 Year |
|
+15.26% |
| 5 Year |
|
+31.92% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -166.09 | 0 | 0 | 0 | 243.83 | 16.47 | 32.19 | -22.22 | -91.91 | |
| Return on Capital Employed (%) | -135.77 | -216.82 | -18.3 | 11.83 | 16.94 | 8.94 | 16.13 | -2.32 | -14.3 | |
| Return on Assets (%) | -33.62 | -92.83 | -11.72 | 4.76 | 6.24 | 1.83 | 5.31 | -3.44 | -8.28 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 0 | -4 | -5 | 2 | 6 | 13 | 18 | 15 | 5 | 0 | |
| Non Curr. Liab. | 1 | 7 | 9 | 25 | 29 | 34 | 37 | 32 | 35 | 33 | |
| Curr. Liab. | 3 | 1 | 7 | 31 | 30 | 39 | 51 | 62 | 76 | 62 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 117 | 96 | |
| Non Curr. Assets | 4 | 4 | 10 | 15 | 18 | 25 | 35 | 36 | 35 | 34 | |
| Curr. Assets | 1 | 1 | 2 | 43 | 48 | 61 | 70 | 73 | 83 | 62 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 117 | 96 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 97 | |
| Other Income | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | |
| Total Income | 2 | 0 | 2 | 77 | 95 | 107 | 135 | 126 | 130 | 99 | |
| Total Expenditure | -4 | -4 | -2 | -74 | -88 | -102 | -124 | -124 | -134 | -107 | |
| PBIDT | -1 | -3 | 0 | 3 | 7 | 5 | 11 | 2 | -4 | -8 | |
| Interest | 0 | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | -5 | |
| Depreciation | 0 | 0 | 0 | -1 | -1 | -2 | -2 | -3 | -3 | -3 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | |
| Exceptional Items | -1 | -1 | |||||||||
| PAT | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -13 | |
| Adjusted EPS | -2 | -5 | -1 | 1 | 3 | 0 | 1 | -1 | -2 | -3 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | |
| Cash Fr. Inv. | 0 | 0 | 0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | |
| Cash Fr. Finan. | 0 | 0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | |
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
|
Fri, 19 Apr 2024
Compliance Certificate Pursuant To Regulation 40(9) Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations 2015. Dear Sir/ Madam Pursuant to Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 please find enclosed herewith certificate issued by Practicing Company Secretary. |
|
Thu, 18 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Dear Sir/ Madam Pursuant to Regulation 39(3) of SEBI ( Listing Obligation and Disclosure Requirements) Regulations 2015. The Company has received the intimation from our Registrar & Transfer Agent Beetal Financial Services Private Limited regarding the request received from issuance of duplicate share certificates. |
|
Wed, 10 Apr 2024
Intimation Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 For Written Confirmation For Active Substances Imported Into The European Union (EU) For Medical Products For Human Use. Dear Sir/ Madam The Company is pleased to inform that the Company has received written confirmation for active substances imported into the European Union for medical products for human use in accordance with Article 46(b)(2)(b) of Directives 2001/83/EC from Government of India Ministry of Health & Family welfare Central Drug Standard Control Organization vide Certificate no. WC-0474. |
| Fri, 26 Apr 2024 |
High Delivery Percentage
|
Opening at High
|
Close Within 52 Week High Zone
|
High Decrease in 1 Month
|
High Increase in 3 Months
|
